Non-Peptidic Small-Molecule Inhibitors of the Single-Chain Hepatitis C Virus NS3 Protease/NS4A Cofactor Complex Discovered by Structure-Based NMR Screening

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2486-2498

  Wyss, Daniel F ^a   Arasappan, Ashok ^a   Senior, Mary M ^a   Wang, Yu Sen ^a   Beyer, Brian M ^a   Njoroge, F George ^a   McCoy, Mark A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; NS3 PROTEASE; NS4A COFACTOR; PROTEIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; BINDING AFFINITY; ENZYME INHIBITION; HEPATITIS C VIRUS; NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANILIDES; BENZENE DERIVATIVES; BINDING SITES; CARRIER PROTEINS; DATABASES, FACTUAL; ENZYME INHIBITORS; HEPACIVIRUS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 2342652311     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0305117     Document Type: Article

References (29)

1. Lauer, G. M.; Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345, 41-52.
2. Bartenschlager, R. Hepatitis C virus replicons: potential role for drug development. Nat. Rev. Drug Discovery 2002, 1, 911-916.
3. Reed, K. E.; Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 2000, 242, 55-84.
4. Tan, S. L.; Pause, A.; Shi, Y.; Sonenberg, N. Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discovery 2002, 1, 867-881.
5. Levin, M. K.; Patel, S. S. Helicase from hepatitis C virus, energetics of DNA binding. J. Biol. Chem. 2002, 277, 29377-29385.
6. (a) Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J. Virol. 1994, 68, 5045-5055.
7. (b) Failla, C.; Tomei, L.; De Francesco, R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 1994, 68, 3753-3760.
8. (c) Lin, C.; Prágai, B. M.; Grakoui, A.; Xu, J.; Rice, C. M. Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics. J. Virol. 1994, 68, 8147-8157.
9. (d) Tanji, Y.; Hijikata, M.; Satoh, S.; Kaneko, T.; Shimotohno, K. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J. Virol. 1995, 69, 1575-1581.
10. (a) Love, R. A.; Parge, H. E.; Wickersham, J. A.; Hostomsky, Z.; Habuka, N.; Moomaw, E. W.; Adachi, T.; Hostomska, Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996, 87, 331-342.
11. (b) Barbato, G.; Cicero, D. O.; Nardi, M. C.; Steinkuehler, C.; Cortese, R.; De Francesco, R.; Bazzo, R. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J. Mol. Biol. 1999, 289, 371-384.
12. (a) Kim, J. L.; Morgenstern, K. A.; Lin, C.; Fox, T.; Dwyer, M. D.; Landro, J. A.; Chambers, S. P.; Markland, W.; Lepre, C. A.; O'Malley, E. T.; Harbeson, S. L.; Rice, C. M.; Murcko, M. A.; Caron, P. R.; Thomson, J. A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996, 87, 343-355.
13. (b) Yan, Y.; Li, Y.; Munshi, S.; Sardana, V.; Cole, J. L.; Sardana, M.; Steinkuehler, C.; Tomei, L.; De Francesco, R.; Kuo, L. C.; Chen, Z. Complex of NS3 pyotease and NS4A peptide of BK strain hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form. Protein Sci. 1998, 7, 837-847.
14. McCoy, M. A.; Senior, M. M.; Gesell, J. J.; Ramanathan, L.; Wyss, D. F. Solution structure and dynamics of the single-chain hepatitis C virus NS3 proteas NS4A cofactor complex. J. Mol. Biol. 2001, 305, 1099-1110.
15. Yao, N.; Reichert, P.; Taremi, S. S.; Prosise, W. W.; Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999, 7, 1353-1363.
16. (a) Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins. Science 1997, 278, 497-499.
17. (b) Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274, 1531-1534.
18. (a) Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Ajay; Murcko, M. A.; Moore, J. M. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem. Biol. 1999, 6, 755-769.
19. (b) Pellecchia, M.; Meininger, D.; Dong, Q.; Chang, E.; Jack, R.; Sem, D. S. NMR-based structural characterization of large protein-ligand interactions. J. Biomol. NMR 2002, 22, 165-173.
20. (c) van Dongen, M.; Weigelt, J.; Uppenberg, J.; Schultz, J.; Wikström, M. Structure-based screening and design in drug discovery. Drug Discovery Today 2002, 7, 471-478.
21. (d) Moy, F. J.; Haraki, K.; Mobilio, D.; Walker, G.; Powers, R.; Tabei, K.; Tong, H.; Siegel, M. M. MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. Anal. Chem. 2001, 73, 571-581.
22. (e) Stockman, B. J.; Dalvit, C. NMR screening techniques in drug discovery and drug design. Prog. Nucl. Magn. Reson. Spectrosc. 2002, 41, 187-231.
23. (f) Meyer, B.; Peters, T. Angew. Chem., Int. Ed. 2003, 42, 864-890.
24. (g) Jahnke, W.; Rüdisser, S.; Zurini, M. Spin label enhanced NMR screening. J. Am. Chem. Soc. 2001, 123, 3149-3150.
25. Wyss, D. F.; McCoy, M. A.; Senior, M. S. NMR-based approaches for lead discovery. Curr. Opin. Drug Discovery Dev. 2002, 5, 630-647.
26. McCoy, M. A.; Wyss, D. F. Spatial localization of ligand binding sites from electron current density surfaces calculated from NMR chemical shift perturbations. J. Am. Chem. Soc. 2002, 124, 11758-11763.
27. McCoy, M. A.; Wyss, D. F. Alignment of weakly interacting molecules to protein surfaces using simulations of chemical shift perturbations. J. Biomol. NMR 2000, 18, 189-198.
28. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadows, R. P.; Steinman, D. H.; Carrera, G. M., Jr.; Marcotte, P. A.; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 1997, 119, 5818-5827.
29. Zhang, R.; Beyer, B. M.; Durkin, J.; Ingram, R.; Njoroge, F. G.; Windsor, W. T.; Malcolm, B. A. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal. Biochem. 1999, 270, 268-275.